Atlas Trials

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Clinical trial NCT04465734 · WITHDRAWN

Trial details

NCT number
NCT04465734
Sponsor
Shanghai Henlius Biotech
Status
WITHDRAWN
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2022-11-15
Primary completion
2023-10-15
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.